acute myeloid leukemia

FDA approves first targeted leukemia drug for certain patients, plus 2 moreLate last week, FDA approved a new drug to treat acute myeloid leukemia (AML), the first treatment for Batten disease, and expanded the use of a current drug to treat liver cancer.
Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Midostaurin extends survival among some AML patients: StudyAML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.
February FDA drug approvalsFDA actions in brief, complete response, breakthrough therapy designation, fast-track designation